Jefferies Financial Group Initiates Coverage on Akero Therapeutics (NASDAQ:AKRO)

Share on StockTwits

Investment analysts at Jefferies Financial Group assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $28.00 price target on the stock. Jefferies Financial Group’s target price points to a potential upside of 36.39% from the stock’s previous close.

AKRO has been the subject of a number of other research reports. JPMorgan Chase & Co. reissued a “sell” rating and issued a $18.00 price objective on shares of ABB in a report on Monday. Roth Capital reissued a “buy” rating on shares of Coeur Mining in a report on Monday.

Shares of NASDAQ AKRO opened at $20.53 on Monday. Akero Therapeutics has a 52 week low of $16.06 and a 52 week high of $21.94.

In other news, major shareholder Global Strategic Fund I. Venbio acquired 250,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average price of $16.00 per share, with a total value of $4,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Seth Loring Harrison acquired 900,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average cost of $16.00 per share, with a total value of $14,400,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Recommended Story: What does it mean to hold a stock in street name?

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report